These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
574 related items for PubMed ID: 12973747
1. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Danysz W, Parsons CG. Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747 [Abstract] [Full Text] [Related]
2. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia]. Tanović A, Alfaro V. Rev Neurol; 2003 Sep; 42(10):607-16. PubMed ID: 16703529 [Abstract] [Full Text] [Related]
3. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Parsons CG, Stöffler A, Danysz W. Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591 [Abstract] [Full Text] [Related]
11. [Efficacy of memantine in the treatment of Alzheimer's disease]. Molinuevo Guix JL, Lladó Plarrumaní A. Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590 [Abstract] [Full Text] [Related]
12. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Volbracht C, van Beek J, Zhu C, Blomgren K, Leist M. Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864 [Abstract] [Full Text] [Related]
13. Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats. Morè L, Gravius A, Nagel J, Valastro B, Greco S, Danysz W. Behav Pharmacol; 2008 Oct; 19(7):724-34. PubMed ID: 18797249 [Abstract] [Full Text] [Related]
14. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Kornhuber J, Weller M. Biol Psychiatry; 1997 Jan 15; 41(2):135-44. PubMed ID: 9018383 [Abstract] [Full Text] [Related]
15. [New therapeutic possibilities with low-affinity NMDA receptor antagonists]. Kornhuber J, Weller M. Nervenarzt; 1996 Jan 15; 67(1):77-82. PubMed ID: 8676993 [Abstract] [Full Text] [Related]
17. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. Rogawski MA, Wenk GL. CNS Drug Rev; 2003 Jan 15; 9(3):275-308. PubMed ID: 14530799 [Abstract] [Full Text] [Related]
18. [The clinical relevance of memantine use]. Sobów T. Psychiatr Pol; 2004 Jan 15; 38(2):321-30. PubMed ID: 15307296 [Abstract] [Full Text] [Related]
19. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Song MS, Rauw G, Baker GB, Kar S. Eur J Neurosci; 2008 Nov 15; 28(10):1989-2002. PubMed ID: 19046381 [Abstract] [Full Text] [Related]
20. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine. Gilling KE, Jatzke C, Parsons CG. Neuropharmacology; 2007 Sep 15; 53(3):415-20. PubMed ID: 17632186 [Abstract] [Full Text] [Related] Page: [Next] [New Search]